GSK will showcase 43 abstracts at the ATS 2025 International Congress, highlighting advancements in treatments for asthma and COPD with mepolizumab and depemokimab.
Leerink Partners analyst maintains a Buy rating for Trevi Therapeutics with a $7.00 price target, citing Haduvio's potential in treating idiopathic pulmonary fibrosis (IPF) cough.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.